文献速递儿童感染儿童呼吸

2024年安徽地区儿童百日咳流行特征、临床特点及鲍特菌耐药模式

[The clinical and epidemiological characteristics of pertussis and antimicrobial resistance patterns of Bordetella pertussis in children in Anhui region in 2024].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2025-01-01

186株分离株对阿奇霉素MIC90>256.000 mg/L,对甲氧苄啶-磺胺甲噁唑MIC90为0.050 mg/L,不推荐经验使用大环内酯类,≥2月龄患儿可首选甲氧苄啶-磺胺甲噁唑。

要点

  • 2024年安徽儿童百日咳高峰在4至7月,9岁及以下儿童占96.3%。
  • 住院患儿中58.5%未接种疫苗,重症百日咳患儿均未接种疫苗。
  • 分离株对阿奇霉素MIC90>256.000 mg/L,不推荐经验使用大环内酯类。

核心结论

  • 2024年安徽地区儿童百日咳发病高峰为4至7月,9岁及以下为主要发病人群,婴儿和学龄前儿童易感,家庭传播率高。
  • 不推荐经验使用大环内酯类治疗百日咳,甲氧苄啶-磺胺甲噁唑可作为≥2月龄百日咳患儿的首选抗生素。

研究设计与样本

  • 暴发期间采集住院患儿及家庭陪护者鼻咽拭子分离百日咳鲍特菌,对186株分离株进行药物敏感性检测。

主要发现

  • 住院患儿301例(7.1%),平均年龄4.4(2.8,16.5)月龄,全程接种61例(20.3%),部分接种64例(21.3%),未接种176例(58.5%)。
  • 20例(6.6%)重症百日咳患儿均未接种疫苗;住院患儿中阵发性痉咳298例(99.0%),合并肺炎228例(75.7%),百日咳脑病5例(1.7%)。
  • 接受筛查的陪护家属感染率为77.1%(371/481)。

关键数值与推荐

  • 基于186株百日咳分离株,阿奇霉素MIC90>256.000 mg/L,甲氧苄啶-磺胺甲噁唑MIC90为0.050 mg/L。
  • 不推荐经验使用大环内酯类药物治疗百日咳。
  • 甲氧苄啶-磺胺甲噁唑可作为≥2月龄百日咳患儿的首选抗生素。

临床怎么用

  • 对疑似百日咳患儿应结合流行季节(4至7月高峰)和年龄(9岁及以下尤其是婴儿和学龄前儿童)提高警惕。
  • 住院患儿中未接种疫苗者比例高,重症均未接种,应重视疫苗接种状态评估。
  • 经验性抗菌治疗不推荐大环内酯类,≥2月龄患儿可优先考虑甲氧苄啶-磺胺甲噁唑。
  • 家庭内传播率高,应对陪护家属进行筛查和防控。

局限性

  • 本研究为单中心前瞻性观察性研究,结果外推需谨慎。
  • 未报告药物敏感性检测的具体方法学细节及临床治疗结局与耐药性的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the epidemiological and clinical characteristics of pertussis in children and the antimicrobial resistance pattern of Bordetella pertussis isolates in Anhui province in 2024. Methods: Prospective observational study. The demographic information of 4 233 cases of pertussis confirmed by nucleic acid testing in Anhui Provincial Children's Hospital in 2024 and the clinical data of hospitalized cases were collected. The annual epidemic trend of pertussis in children, the clinical characteristics of hospitalized cases, and the vaccination status were analyzed. Bordetella pertussis isolates were recovered from nasopharyngeal swabs obtained from hospitalized children and their family caregivers during the outbreak period and antimicrobial susceptibility was tested. Results: Among the 4 233 children, 2 330 were male and 1 903 were female. A total of 4 059 cases (95.9%) occurred from March to September, with the peak of the disease from April to July (3 364 cases (79.5%)).There were 4 075 cases (96.3%) aged 9 years and under, among which 718 cases (17.0%) were under 1 year old and 2 494 cases (58.9%) were aged 4 to 7 years. During the outbreak period, there were a total of 301 hospitalized children (7.1%), with an average age of 4.4 (2.8, 16.5) months. Among them, 61 cases (20.3%) received the full course of vaccination (4 doses), 64 cases (21.3%) received partial doses of the vaccine, and 176 cases (58.5%) were unvaccinated. Among the unvaccinated children, 79.6% (172/216) were under 1 year old, 8.7% (2/23) were between 1 and 3 years old, and 3.2% (2/62) were 3 years old or older. None of the 20 cases (6.6%) of severe pertussis received pertussis vaccine.Among the 301 hospitalized children, 298 cases (99.0%) presented with typical paroxysmal spasmodic cough, 94 cases (31.2%) had vomiting after coughing, 82 cases (27.2%) had whooping sounds, and 54 cases (17.9%) had cyanotic attacks. There were 228 cases (75.7%) complicated with pneumonia and 5 cases (1.7%) with pertussis encephalopathy. The infection rate among the accompanying family members who underwent screening was 77.1% (371/481). Based on the minimum inhibitory concentration testing of 186 Bordetella pertussis isolates, the minimum inhibitory concentration 90 of azithromycin and trimethoprim-sulfamethoxazole were >256.000 and 0.050 mg/L, respectively. Conclusions: The peak of pertussis cases in Anhui region in 2024 occurred from April to July. Children aged ≤9 years were the major affected population. Infants and preschool children were most susceptible to pertussis. The intrafamily transmission rate of pertussis is high. Empirical use of macrolides for the treatment of pertussis is not recommended. Trimethoprim-sulfamethoxazole can be used as the preferred antibiotic for pertussis in children aged 2 months and above. 目的: 分析2024年安徽地区儿童百日咳流行特征、临床特点及百日咳鲍特菌的耐药模式。 方法: 前瞻性观察性研究。收集2024年全年安徽省儿童医院经核酸确诊的4 233例百日咳患儿的人口学信息。分析百日咳患儿的全年流行趋势及其中暴发时期住院患儿的临床特点和疫苗接种状态。流行高峰期间采集住院患儿及其家庭陪护者的鼻咽拭子标本进行百日咳鲍特菌分离和药物敏感性检测。 结果: 4 233例患儿中,男2 330例、女1 903例,3至9月为百日咳患儿暴发时期[4 059例(95.9%)],其中4至7月达到发病高峰[3 364例(79.5%)]。9岁及以下4 075例(96.3%),其中1岁以下718例(17.0%)、4~7岁2 494例(58.9%)。暴发时期共有住院患儿301例(7.1%),住院年龄4.4(2.8,16.5)月龄,61例(20.3%)患儿全程(4剂次)接种疫苗,64例(21.3%)接种部分剂次疫苗,176例(58.5%)未接种疫苗,未接种中<1岁79.6%(172/216)、1~<3岁8.7%(2/23)和≥3岁3.2%(2/62)。20例(6.6%)重症百日咳患儿均未接种疫苗。301例住院患儿中,典型的阵发性痉咳298例(99.0%),咳嗽后呕吐94例(31.2%),鸡鸣样回声82例(27.2%),发绀54例(17.9%);合并肺炎228例(75.7%),合并百日咳脑病5例(1.7%)。接受筛查的陪护家属感染率为77.1%(371/481)。基于186株百日咳分离株的最低抑菌浓度检测,阿奇霉素和甲氧苄啶-磺胺甲噁唑的最低抑菌浓度90分别为>256.000、0.050 mg/L。 结论: 2024年安徽地区百日咳疫情的发病高峰出现在4至7月。9岁及以下是主要发病人群。婴儿和学龄前儿童易感。百日咳家庭传播率高。不推荐经验使用大环内酯类药物治疗百日咳。甲氧苄啶-磺胺甲噁唑可作为≥2月龄百日咳患儿的首选抗生素。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zeng XY, Chen BQ, Ma H, et al. [The clinical and epidemiological characteristics of pertussis and antimicrobial resistance patterns of Bordetella pertussis in children in Anhui region in 2024]. Zhonghua Er Ke Za Zhi. 2025. PMID: 40692455. doi:10.3760/cma.j.cn112140-20250326-00256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。